Completed PHASE1 INTERVENTIONAL 4-arm NCT06072157

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AK006 in Healthy Subjects and in Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria

Sponsor: Allakos Inc.

Conditions Chronic Spontaneous Urticaria Healthy Participants

Interventions AK006-IV AK006-SC Placebo-IV Placebo-SC

Updated 11 times since 2023 Last updated: Jun 2, 2025 Started: Aug 28, 2023 Primary completion: May 12, 2025 Completion: May 12, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Chronic Spontaneous Urticaria and Healthy Participants, this trial is completed. The trial is conducted by Allakos Inc. and has accumulated 11 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Jun 2025 — Sep 2025 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Feb 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Oct 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1

▶ Show 6 earlier versions

Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Mar 2024 [monthly]

Recruiting PHASE1

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allakos Inc.

Data source: Allakos Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Bakersfield, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Brooklyn, United States , Calgary, Canada , Cincinnati, United States , Colorado Springs, United States , El Paso, United States and 14 more locations